Tocagen, which is developing a combination gene therapy treatment for brain cancer, raised $85 million by offering 8.5 million shares at $10. It had planned to offer 7.25 million shares at a range of $10 to $12. Tocagen plans to list on the Nasdaq under the symbol TOCA. Leerink Partners, Evercore ISI and Stifel acted as lead managers on the deal.
